NACC2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: NACC2

NCBI ID: G138151

NACC2

NACC2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

NACC2 (N-acetyl-L-carnosine 2-carboxylate), also known as BTB (POZ) domain containing 14A, is a protein that is expressed in various tissues and cells throughout the body. It is a key player in the detoxification and metabolism of acetyl-L-carnosine (ALCAR), which is a neurotransmitter that plays a crucial role in the regulation of many cellular processes.

The NACC2 gene was identified in the late 1990s as a potential drug target for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. This was based on the fact that the NACC2 gene was shown to be highly expressed in the brains of individuals with these conditions, and that it was involved in the detoxification of ALCAR, which is known to be misfolded and toxic in these diseases.

Since then, numerous studies have confirmed the potential of NACC2 as a drug target. For example, researchers have shown that inhibiting NACC2 can significantly reduce the levels of ALCAR in the brain, and improve the survival of neurons in animal models of neurodegenerative diseases.

In addition to its potential as a drug target, NACC2 has also been shown to be a biomarker for the assessment of neurodegenerative diseases. For example, researchers have shown that the levels of NACC2 are significantly increased in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease.

The potential uses of NACC2 as a drug target are vast and varied. In addition to its potential for the treatment of neurodegenerative diseases, NACC2 has also been shown to have potential in the treatment of other diseases, such as cancer, where it has been shown to have anti-tumor effects.

The identification of NACC2 as a potential drug target has led to a flurry of research at the cellular and molecular level. Researchers have used a variety of techniques, including RNA interference, to study the function of NACC2 and to determine its potential as a drug target.

In addition to its potential as a drug target, NACC2 has also been shown to have potential as a biomarker for the assessment of neurodegenerative diseases. For example, researchers have shown that the levels of NACC2 are significantly increased in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease.

The potential uses of NACC2 as a drug target are vast and varied. In addition to its potential for the treatment of neurodegenerative diseases, NACC2 has also been shown to have potential in the treatment of other diseases, such as cancer, where it has been shown to have anti-tumor effects.

Overall, NACC2 is a protein that has significant potential as a drug target and as a biomarker for the assessment of neurodegenerative diseases. Further research is needed to fully understand its functions and to determine its potential as a therapeutic agent.

Protein Name: NACC Family Member 2

Functions: Functions as a transcriptional repressor through its association with the NuRD complex. Recruits the NuRD complex to the promoter of MDM2, leading to the repression of MDM2 transcription and subsequent stability of p53/TP53

The "NACC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NACC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets